Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholate for the primary treatment of invasive candidiasis. METHODS: We enrolled patients who had clinical evidence of infection and a positive culture for candida species from blood or another site. Patients were stratified according to the severity of disease, as indicated by the Acute Physiology and Chronic Health Evaluation (APACHE II) score, and the presence or absence of neutropenia and were randomly assigned to receive either caspofungin or amphotericin B. The study was designed to compare the efficacy of caspofungin with that of amphotericin B in patients with invasive candidiasis and in a subgroup with candidemia. RESULTS: Of the 239 patients enrolled, 224 were included in the modified intention-to-treat analysis. Base-line characteristics, including the percentage of patients with neutropenia and the mean APACHE II score, were similar in the two treatment groups. A modified intention-to-treat analysis showed that the efficacy of caspofungin was similar to that of amphotericin B, with successful outcomes in 73.4 percent of the patients treated with caspofungin and in 61.7 percent of those treated with amphotericin B (difference after adjustment for APACHE II score and neutropenic status, 12.7 percentage points; 95.6 percent confidence interval, -0.7 to 26.0). An analysis of patients who met prespecified criteria for evaluation showed that caspofungin was superior, with a favorable response in 80.7 percent of patients, as compared with 64.9 percent of those who received amphotericin B (difference, 15.4 percentage points; 95.6 percent confidence interval, 1.1 to 29.7). Caspofungin was as effective as amphotericin B in patients who had candidemia, with a favorable response in 71.7 percent and 62.8 percent of patients, respectively (difference, 10.0 percentage points; 95.0 percent confidence interval, -4.5 to 24.5). There were significantly fewer drug-related adverse events in the caspofungin group than in the amphotericin B group. CONCLUSIONS: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For invasive candidiasis, echinocandins were a great development that lowered the mortality associated with these infections, with low toxicity and few interactions with other medication (Mora-Duarte et al., 2002; Pappas et al., 2016).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Mora-Duarte et al., 2002
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Nguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C. E., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Self-citationVillanueva, A., Gotuzzo, E., Arathoon, E. G., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J., & Sable, C. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01191-9 · Cited by 292
Self-citation
Research works printed but not linked: 4
- Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis, and treatment. 2nd ed. New York: Raven Press, 1992:279-329.
- Yamamura DL, 1999, CMAJ, 160, 493
- Bachman SP, Pera S, Kirkpatrick WR, Patterson TF, Lopez-Ribot JL. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000. Washington, D.C.: American Society for Microbiology, 2000:352. abstract.
- Nucci M, Santos LM, Ferradosa AS, Colombo AL. Epidemiology of candidemia due to C. parapsilosis in tertiary care hospitals in Brazil. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2001:393. abstract.
Cited by
Items 401–500 of 1,000
Martial, L. C., Brüggemann, R. J. M., Schouten, J. A., van Leeuwen, H. J., van Zanten, A. R. H., de Lange, D. W., Muilwijk, E. W., Verweij, P. E., Burger, D. M., Aarnoutse, R. E., et al. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0347-2 · Cited by 45
Bader, J. C., Lakota, E. A., Flanagan, S., Ong, V., Sandison, T., Rubino, C. M., Bhavnani, S. M., & Ambrose, P. G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02614-17 · Cited by 45
Emerging Issues in Antifungal Resistance
Perfect, J. R., & Ghannoum, M. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.05.003 · Cited by 47
Self-citationGroll, A. H., Silling, G., Young, C., Schwerdtfeger, R., Ostermann, H., Heinz, W. J., Gerss, J., Kolve, H., Lanvers-Kaminsky, C., Vieira Pinheiro, J. P., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00425-10 · Cited by 44
Nanocarrier-based topical drug delivery for an antifungal drug
Hussain, A., Samad, A., Nazish, I., & Ahmed, F. J. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.771647 · Cited by 44
Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship
Mellinghoff, S. C., Hartmann, P., Cornely, F. B., Knauth, L., Koehler, F. C., Köhler, P., Krause, C., Kronenberg, C., Kranz, S.-L., Menon, V. P., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3285-8 · Cited by 49
Antifungal treatment in pediatric patients
Zaoutis, T. E., Benjamin, D. K., & Steinbach, W. J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.06.005 · Cited by 47
Zilberberg, M. D., & Shorr, A. F. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.04.008 · Cited by 42
“In this noninferiority trial stratifying patients based on the presence of neutropenia, caspofungin performed as well as AMB in terms of the primary outcome of favorable response, regardless of the presence or absence of neutropenia.(80) In an analysis of a predefined subpopulation of per-protocol subjects, caspofungi…”
Antifúngicos sistémicos. Farmacodinamia y farmacocinética
Catalán, M., & Montejo, J. C. (2006) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(06)70012-2 · Cited by 86
Playford, E. G., Eggimann, P., & Calandra, T. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283177967 · Cited by 46
Saner, F. H., Gensicke, J., Rath, P. ‐., Frühauf, N. R., Gu, Y., Paul, A., Radtke, A., Malagó, M., & Broelsch, C. E. (2006) · Infection · doi:10.1007/s15010-006-5657-8 · Cited by 42
Prevention and treatment of invasive fungal diseases in neutropenic patients
Almyroudis, N. G., & Segal, B. H. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32832e074d · Cited by 46
Singh, G., Imai, J. K., Clemons, K. V., & Stevens, D. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1369-1376.2005 · Cited by 42
Voriconazole: review of a broad spectrum triazole antifungal agent
Kofla, G., & Ruhnke, M. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.7.1215 · Cited by 47
Changing face of health-care associated fungal infections
Billé, J., Marchetti, O., & Calandra, T. (2005) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000171924.39828.fb · Cited by 42
Early Clinical Experience with Anidulafungin at a Large Tertiary Care Medical Center
Brielmaier, B. D., Casabar, E., Kurtzeborn, C. M., McKinnon, P. S., & Ritchie, D. J. (2008) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.1.64 · Cited by 42
Echinocandins — First-Choice or First-Line Therapy for Invasive Candidiasis?
Sobel, J. D., & Revankar, S. G. (2007) · New England Journal of Medicine · doi:10.1056/nejme078078 · Cited by 42
Intra-abdominal Sepsis: Newer Interventional and Antimicrobial Therapies
Solomkin, J. S., & Mazuski, J. E. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.04.007 · Cited by 50
An Italian consensus for invasive candidiasis management (ITALIC)
Scudeller, L., Viscoli, C., Menichetti, F., Bono, V. D., Cristini, F., Tascini, C., Bassetti, M., & Viale, P. (2013) · Infection · doi:10.1007/s15010-013-0558-0 · Cited by 49
Colombo, A. L., Ngai, A. L., Bourque, M., Bradshaw, S. K., Strohmaier, K. M., Taylor, A. F., Lupinacci, R. J., & Kartsonis, N. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00911-09 · Cited by 41
Self-citationEchinocandin Resistance in Candida Species: a Review of Recent Developments
Wiederhold, N. P. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0549-2 · Cited by 48
Kumar, A., Zarychanski, R., Pisipati, A., Kumar, A., Kethireddy, S., & Bow, E. J. (2018) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2017.1421592 · Cited by 47
Reuter, C. W., Morgan, M. A., Bange, F., Gunzer, F., Eder, M., Hertenstein, B., & Ganser, A. (2005) · Clinical Infectious Diseases · doi:10.1086/497079 · Cited by 49
Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis
Mills, E. J., Perri, D., Cooper, C., Nachega, J. B., Wu, P., Tleyjeh, I. M., & Phillips, P. (2009) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-8-23 · Cited by 45
Guinea, J., Peláez, T., Alcalá, L., Ruiz-Serrano, M. J., & Bouza, E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3495-3497.2005 · Cited by 41
Jimenez-Exposito, M. J., Torres, G., Baraldés, A., Benito, N., Marco, F., Paré, J. C., Moreno, A. D., Claramonte, X., Mestres, C. A., Almela, M., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/424018 · Cited by 42
Self-citationOliva, A., Rosa, F. G. D., Mikulska, M., Pea, F., Sanguinetti, M., Tascini, C., & Venditti, M. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2240956 · Cited by 51
Zaragoza, R., Perman, J., Salavert, M., Viudes, Solé, A., Jarque, I., Cantón, R., Monte‐Boquet, E., & Romá, E. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3994 · Cited by 46
Rocha, W. P. D. S., Lemos, V. L. D. B., Ferreira, M. R. A., Soares, L. A. L., Svidzisnki, T. I. E., Milan, E. P., & Chaves, G. M. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0522-x · Cited by 48
Cesaro, S., Tridello, G., Blijlevens, N. M. A., Ljungman, P. T., Craddock, C., Michallet, M., Martin, A. M., Snowden, J. A., Mohty, M., Maertens, J. A., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy150 · Cited by 42
Posaconazole in the management of refractory invasive fungal infections
Neumeister, P. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3329 · Cited by 44
Cornely, O. A., Sidhu, M., Odeyemi, I., van Engen, A. K., van der Waal, J. M., & Schoeman, O. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802124889 · Cited by 41
Glasmacher, A. G., Cornely, O. A., Orlopp, K. S., Reuter, S., Blaschke, S., Eichel, M., Silling, G., Simons, B., Egerer, G., Siemann, M., et al. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki410 · Cited by 41
Trenschel, R., Ditschkowski, M., Elmaagacli, A. H., Koldehoff, M., Ottinger, H., Steckel, N. K., Hlinka, M., Peceny, R., Rath, P., Dermoumi, H. L., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704859 · Cited by 40
Critical care considerations of hematopoietic stem cell transplantation
Soubani, A. O. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000231886.80470.b6 · Cited by 45
(2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.00735.x · Cited by 40
Update on antifungal treatment of invasive Candida and Aspergillus infections
Maschmeyer, G., & Ruhnke, M. (2004) · Mycoses · doi:10.1111/j.1439-0507.2004.01003.x · Cited by 49
Management of fever and neutropenia in the adult patient with acute myeloid leukemia
Peseski, A. M., McClean, M., Green, S. D., Beeler, C., & Koenig, H. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1820863 · Cited by 44
Randomized clinical trials: what gets published, and when?
Hirsch, L. (2004) · Europe PMC (PubMed Central) · Cited by 39
Update on management of infections in cancer and stem cell transplant patients
Neuburger, S., & Maschmeyer, G. (2006) · Annals of Hematology · doi:10.1007/s00277-005-0048-2 · Cited by 43
Investigation of the antifungal activity of carvacrol against strains ofCryptococcus neoformans
Nóbrega, R. D. O., Teixeira, A. P. D. C., de Oliveira, W. A., Lima, E. D. O., & Lima, I. O. (2016) · Pharmaceutical Biology · doi:10.3109/13880209.2016.1172319 · Cited by 41
Design of Efficacy Trials of Cytokines in Combination with Antifungal Drugs
Kullberg, B. J., Lashof, A. M. L. O., & Netea, M. G. (2004) · Clinical Infectious Diseases · doi:10.1086/421960 · Cited by 39
Grela, E., Piet, M., Luchowski, R., Grudzinski, W., Paduch, R., & Gruszecki, W. I. (2018) · Scientific Reports · doi:10.1038/s41598-018-32301-9 · Cited by 38
Moellering, R. C., Graybill, J. R., McGowan, J. E., & Corey, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.08.001 · Cited by 44
Nguyen, K. T., Ta, P., Hoang, B. T., Cheng, S., Hao, B., Nguyen, M. H., & Clancy, C. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01480-08 · Cited by 38
Addition of Caspofungin to Fluconazole Does Not Improve Outcome in Murine Candidiasis
Graybill, J. R., Bocanegra, R., Najvar, L. K., Hernandez, S., & Larsen, R. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2373-2375.2003 · Cited by 38
Invasive candidiasis and candidemia: from current opinions to future perspectives
Rüping, M., Vehreschild, J. J., & Cornely, O. A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902911440 · Cited by 46
Kale‐Pradhan, P. B., Morgan, G., Wilhelm, S. M., & Johnson, L. B. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.12.1207 · Cited by 37
The epidemiology of non‐Candida yeast isolated from blood: The Asia Surveillance Study
Lin, S., Lu, P., Tan, B. H., Chakrabarti, A., Wu, U., Yang, J.-H., Patel, A. K., Li, R. Y., Watcharananan, S. P., Liu, Z., et al. (2018) · Mycoses · doi:10.1111/myc.12852 · Cited by 45
Louie, A., Stein, D. S., Zack, J. Z., Liu, W., Conde, H., Fregeau, C., VanScoy, B. D., & Drusano, G. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01324-10 · Cited by 37
Anidulafungin: an echinocandin antifungal
Pfaller, M. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1183 · Cited by 38
SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTS
Zaoutis, T., Lehrnbecher, T., Groll, A. H., Steinbach, W. J., Jafri, H. S., Maertens, J., Ngai, A. L., Chow, J. W., Taylor, A. F., Strohmaier, K. M., et al. (2009) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181af5a15 · Cited by 40
Self-citationCombination antifungal therapy: what can and should we expect?
Johnson, M. D., & Perfect, J. R. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705687 · Cited by 39
Self-citationCaspofungin in Combination with Amphotericin B against Candida parapsilosis
Barchiesi, F., Spreghini, E., Tomassetti, S., Giannini, D., & Scalise, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00880-06 · Cited by 45
Persistent Candidemia: Causes and Investigations
Nucci, M. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0039-1 · Cited by 37
Fungal infections in severe acute pancreatitis
Kochhar, R. K., Noor, M. T., & Wig, J. D. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06685.x · Cited by 38
Invasive mycoses following trauma
Hajdú, Š., Obradovic, A., Presterl, E., & Vécsei, V. (2008) · Injury · doi:10.1016/j.injury.2008.03.034 · Cited by 38
How urgent is the need for new antifungals?
Stewart, A. G., & Paterson, D. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1935868 · Cited by 36
Fungal Infections: Their Diagnosis and Treatment in Transplant Recipients
Thiel, D. H. V., George, M., & Moore, C. M. (2012) · International Journal of Hepatology · doi:10.1155/2012/106923 · Cited by 39
Population Pharmacokinetics and Pharmacodynamics of Caspofungin in Pediatric Patients
Li, C., Sun, P. G., Dong, Y., Bi, S., Desai, R., Dockendorf, M. F., Kartsonis, N. A., Ngai, A. L., Bradshaw, S. K., & Stone, J. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00905-10 · Cited by 37
Self-citationCandidemia in patients with diabetes mellitus: epidemiology and predictors of mortality
Bader, M. S., Lai, S. M., Kumar, V., & Hinthorn, D. (2004) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410021126 · Cited by 37
Epidemiology, Risk Factors, and Therapy of Candidemia in Pediatric Hematological Patients
Cugno, C., & Cesaro, S. (2012) · Pediatric Reports · doi:10.4081/pr.2012.e9 · Cited by 37
Smith, P. B., Steinbach, W. J., & Benjamin, D. K. (2005) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2005.05.007 · Cited by 42
Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients
Hamza, N. S., Ghannoum, M. A., & Lazarus, H. M. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704603 · Cited by 36
Eficiência terapêutica das formulações lipídicas de anfotericina B
Filippin-Monteiro, F. B., & Souza, L. C. (2006) · Revista Brasileira De Ciencias Farmaceuticas · doi:10.1590/s1516-93322006000200003 · Cited by 81
Bow, E. J. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06906.x · Cited by 39
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35
Alothman, A. F., Al-Musawi, T., Al-Abdely, H. M., Salman, J. A., Almaslamani, M., Yared, N., Butt, A. A., Raghubir, N., Morsi, W. E., & Althaqafi, A. (2013) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2013.08.002 · Cited by 41
Combination antifungal therapy
Patterson, T. F. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000070843.65157.31 · Cited by 35
Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies
Gumbo, T. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3282f1bea3 · Cited by 35
Candidemia in the 21st Century
Chang, A., Neofytos, D., & Horn, D. (2008) · Future Microbiology · doi:10.2217/17460913.3.4.463 · Cited by 43
Egger, S. S., Meier, S., Leu, C.-Y., Christen, S. E., Gratwohl, A. A., Krähenbühl, S., & Haschke, M. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.325 · Cited by 37
Mohamed, W. A. W., & Ismail, M. (2011) · Journal of Tropical Pediatrics · doi:10.1093/tropej/fmr025 · Cited by 36
Candidemia in Burn Patients: Figures and Facts
Pedrosa, A. F., & Rodrigues, A. G. (2011) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3181f2d4fb · Cited by 37
Antifungal treatment strategies in high risk patients
Rüping, M. J. G. T., Vehreschild, J. J., & Cornely, O. A. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01572.x · Cited by 38
Recommendations for the management of candidemia in children in Latin America
Santolaya, M. E., Telles, F. D. Q., Matute, T. A., Colombo, A. L., Zurita, J., Tiraboschi, I. N., Cortés, J. A., Thompson-Moya, L., Guzmán-Blanco, M., Sifuentes‐Osornio, J., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.05.010 · Cited by 38
Self-citationBacak, V., Biočina, B., Starčević, B., Gertler, S., & Begovać, J. (2005) · Journal of Infection · doi:10.1016/j.jinf.2005.10.003 · Cited by 34
Amphotericin B lipid complex for the treatment of invasive fungal infections
Linden, P. K. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.11.2099 · Cited by 35
Interactions of Yeasts, Moulds, and Antifungal Agents: How to Detect Resistance
Hall, G. S. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5 · Cited by 43
Invasive Candida infections in the neonate
Smith, P. B., Steinbach, W. J., & Benjamin, D. K. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.007 · Cited by 36
Invasive candidiasis: update on current pharmacotherapy options and future perspectives
Tragiannidis, A., Tsoulas, C., Kerl, K., & Groll, A. H. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.805204 · Cited by 40
Swoboda, S., Lichtenstern, C., Ober, M. C., Taylor, L. A., Störzinger, D., Michel, A., Brobeil, A., Mieth, M., Hofer, S., Sonntag, H., et al. (2009) · Chemotherapy · doi:10.1159/000264672 · Cited by 34
Candida spp. bloodstream infection: influence of antifungal treatment on outcome
Ortega, M., Marco, F., Soriano, À., Almela, M., Martínez, J. A., Pitart, C., & Mensa, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp495 · Cited by 33
Fungal Infections in Transplant and Oncology Patients
Person, A. K., Kontoyiannis, D. P., & Alexander, B. D. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.11.013 · Cited by 33
Peterson, J. F., Pfaller, M. A., Diekema, D. J., Rinaldi, M. G., Riebe, K. M., & Ledeboer, N. A. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02517-10 · Cited by 39
Apostolidis, J. P., Bouzani, M., Platsouka, E. D., Belasiotou, H., Stamouli, M., Harhalakis, N., Boutati, E. I., Paniara, O., & Nikiforakis, E. (2003) · Clinical Infectious Diseases · doi:10.1086/374895 · Cited by 33
Candidemia y candidiasis invasora en el adulto. Formas clínicas y tratamiento
Cervera, C. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2012.02.003 · Cited by 48
Guinea, J., & Bouza, E. (2008) · Future Microbiology · doi:10.2217/17460913.3.6.603 · Cited by 33
Managing bloodstream infections in patients who have short-term central venous catheters
O’Grady, N. P., & Chertow, D. S. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77a.10015 · Cited by 32
Kurland, S., Furebring, M., Löwdin, E., Eliasson, E., Nielsen, E. I., & Sjölin, J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02466-18 · Cited by 32
Groll, A. H., & Ritter, J. (2005) · Klinische Pädiatrie · doi:10.1055/s-2005-872501 · Cited by 37
EFFICACY AND SAFETY OF CASPOFUNGIN THERAPY IN CHILDREN WITH INVASIVE FUNGAL INFECTIONS
Merlin, É., Galambrun, C., Ribaud, P., Blanc, T., Michel, G., Auvrignon, A., & St??phan, J.-L. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000246844.42159.a0 · Cited by 32
Treatment of opportunistic mycoses: how long is long enough?
Singh, N. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00802-8 · Cited by 36
Candidaemia in a large teaching hospital: a clinical audit
Aliyu, S. H. (2006) · QJM · doi:10.1093/qjmed/hcl087 · Cited by 31
Safety and Pharmacokinetics of Higher Doses of Caspofungin in Healthy Adult Participants
Migoya, E. M., Mistry, G. C., Stone, J. A., Comisar, W. A., Sun, P. G., Norcross, A., Bi, S., Winchell, G. A., Ghosh, K., Uemera, N., et al. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010374853 · Cited by 32
Pulmonary Infections Following Lung Transplantation
Witt, C. A., Meyers, B. F., & Hachem, R. R. (2012) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2012.04.006 · Cited by 36
Antifungal pharmacotherapy for neonatal candidiasis
Bliss, J. M., Wellington, M. A., & Gigliotti, F. (2003) · Seminars in Perinatology · doi:10.1016/s0146-0005(03)00060-0 · Cited by 32
Wilson, D. T., Drew, R. H., & Perfect, J. R. (2009) · Mycopathologia · doi:10.1007/s11046-009-9193-9 · Cited by 34
Self-citationSafety of micafungin in infants: insights into optimal dosing
Ascher, S. B., Smith, P. B., & Benjamin, D. K. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.545345 · Cited by 34
The End of an Era in Defining the Optimal Treatment of Invasive Candidiasis
Clancy, C. J., & Nguyen, M. H. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis023 · Cited by 31
Metadata
- Authors
- Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J.
- Affiliations
- Costa Rican Department of Social Security (CR)
- University of Rochester (US)
- McMaster University (CA)
- Universidade Federal de São Paulo (BR)
- Clinica Santa Maria (CL)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-12-19
- Volume
- 347
- Issue
- 25
- Pages
- 2020-2029
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003661565
- Cited by
- 1,380
- References
- 31
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 17 · 2023: 14 · 2022: 18 · 2021: 30 · 2020: 28 · 2019: 30 · 2018: 29 · 2017: 44 · 2016: 30 · 2015: 50 · 2014: 44 · 2013: 53 · 2012: 62
- FWCI
- 56.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, amphotericin B deoxycholate, invasive candidiasis, candidemia, echinocandins, antifungal therapy, treatment efficacy, drug-related adverse events, neutropenia, APACHE II score, Candida species, randomized trial comparison, length of hospital stay, cost-effectiveness
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candida, Candidiasis, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Peptides, Peptides, Cyclic, Recurrence, Fungemia, APACHE, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.